Capricor Therapeutics Inc (NASDAQ:CAPR – Get Rating) shares crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $4.32 and traded as high as $4.77. Capricor Therapeutics shares last traded at $4.64, with a volume of 71,917 shares changing hands.
Capricor Therapeutics Stock Performance
The business’s fifty day simple moving average is $4.32 and its 200-day simple moving average is $4.78. The firm has a market capitalization of $117.11 million, a PE ratio of -4.11 and a beta of 4.07.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of CAPR. BlackRock Inc. boosted its position in shares of Capricor Therapeutics by 46.3% during the 3rd quarter. BlackRock Inc. now owns 437,228 shares of the biotechnology company’s stock valued at $2,623,000 after acquiring an additional 138,347 shares during the last quarter. Vanguard Group Inc. lifted its position in Capricor Therapeutics by 5.6% in the first quarter. Vanguard Group Inc. now owns 1,020,998 shares of the biotechnology company’s stock worth $3,502,000 after buying an additional 54,260 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Capricor Therapeutics by 54.7% in the first quarter. Dimensional Fund Advisors LP now owns 148,768 shares of the biotechnology company’s stock worth $510,000 after buying an additional 52,611 shares during the last quarter. Marshall Wace LLP bought a new stake in Capricor Therapeutics in the fourth quarter worth $109,000. Finally, Millennium Management LLC lifted its position in Capricor Therapeutics by 93.2% in the fourth quarter. Millennium Management LLC now owns 52,728 shares of the biotechnology company’s stock worth $204,000 after buying an additional 25,440 shares during the last quarter. 11.06% of the stock is currently owned by institutional investors.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
- Get a free copy of the StockNews.com research report on Capricor Therapeutics (CAPR)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.